These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 6100607)

  • 41. Converting enzyme inhibition in mild and moderate essential hypertension. II.
    Rasmussen S; Leth A; Ibsen H; Damkjaer Nielsen M; Nielsen F; Giese J
    Acta Med Scand; 1986; 219(1):29-36. PubMed ID: 3006449
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacology of angiotensin converting enzyme inhibitors. A review.
    Nelson EB; Pool JL; Taylor AA
    Am J Med; 1986 Oct; 81(4C):13-8. PubMed ID: 3022580
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hormonal and blood pressure changes during converting enzyme inhibition by teprotide.
    VandenBurg MJ; Sharman VL; Morton JJ; Williams GH; Marsh FP
    Postgrad Med J; 1981 May; 57(667):283-8. PubMed ID: 6170971
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Need for both angiotensin converting enzyme and angiotensinase specific inhibition for a reliable assessment of angiotensin II levels in human plasma.
    Boddi M; Coppo M; Rostagno C; Gensini GF; Serneri GG
    Clin Chim Acta; 1992 May; 207(3):251-5. PubMed ID: 1327584
    [No Abstract]   [Full Text] [Related]  

  • 45. Involvement of Renin-Angiotensin System in Damage of Angiotensin-Converting Enzyme Inhibitor Captopril on Bone of Normal Mice.
    Liu JX; Wang L; Zhang Y
    Biol Pharm Bull; 2015; 38(6):869-75. PubMed ID: 26027826
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibitors of angiotensin I converting enzyme for treating hypertension.
    Br Med J; 1980 Sep; 281(6241):630-1. PubMed ID: 6159943
    [No Abstract]   [Full Text] [Related]  

  • 47. Biological significance of active and inactive renin in man.
    Lijnen P; Amery A; Fagard R; Verschueren L
    J Endocrinol; 1980 Apr; 85(1):137-43. PubMed ID: 6993602
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Angiotensin-converting enzyme inhibition: a pathophysiologically based concept for the therapy of hypertension and heart failure].
    Stumpe KO; Overlack A; Kolloch R
    Dtsch Med Wochenschr; 1984 Aug; 109(34):1295-9. PubMed ID: 6088205
    [No Abstract]   [Full Text] [Related]  

  • 49. [Physiologically active peptides and the regulation of arterial pressure in normal and pathological states].
    Gomazkov OA
    Vopr Med Khim; 1984; 30(3):79-86. PubMed ID: 6089432
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An overview of angiotensin-converting enzyme inhibitors in the treatment of hypertension.
    Weber MA
    J Am Osteopath Assoc; 1987 Feb; 87(2 Suppl):175-80. PubMed ID: 3030978
    [No Abstract]   [Full Text] [Related]  

  • 51. Captopril combined with thiazide lowers renin substrate concentration: implications for methodology in renin assays.
    Rasmussen S; Damkjaer Nielsen M; Giese J
    Clin Sci (Lond); 1981 May; 60(5):591-3. PubMed ID: 7018804
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects.
    Pellacani A; Brunner HR; Nussberger J
    Clin Sci (Lond); 1994 Nov; 87(5):567-74. PubMed ID: 7874846
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of angiotensin-converting enzyme by des-Leu10-angiotensin I: a potential mechanism of endogenous angiotensin-converting enzyme regulation.
    Snyder RA; Wintroub BU
    Biochim Biophys Acta; 1986 May; 871(1):1-5. PubMed ID: 3008847
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Drugs that block the angiotensin converting enzyme].
    Di Perr T
    Recenti Prog Med; 1985 May; 76(5):276-80. PubMed ID: 2992056
    [No Abstract]   [Full Text] [Related]  

  • 55. In vitro study on the effects of bradykinin potentiating factor and angiotensin II analogue on degradation and conversion of angiotensin I and II in plasma.
    Ogihara T; Yamamoto T; Doi K; Kumahara Y; Kimura T
    Clin Chim Acta; 1974 May; 52(3):287-92. PubMed ID: 4365353
    [No Abstract]   [Full Text] [Related]  

  • 56. [Angiotensin converting enzyme inhibitors].
    Abe K
    Nihon Rinsho; 1985 May; 43(5):949-55. PubMed ID: 2993706
    [No Abstract]   [Full Text] [Related]  

  • 57. Endocrine profile in the long-term phase of converting-enzyme inhibition.
    Swartz SL; Williams GH; Hollenberg NK; Crantz FR; Moore TJ; Levine L; Sasahara AA; Dluhy RG
    Clin Pharmacol Ther; 1980 Oct; 28(4):499-508. PubMed ID: 6250761
    [No Abstract]   [Full Text] [Related]  

  • 58. Opposite effects of captopril on angiotensin I-converting enzyme 'activity' and 'concentration'; relation between enzyme inhibition and long-term blood pressure response.
    Boomsma F; de Bruyn JH; Derkx FH; Schalekamp MA
    Clin Sci (Lond); 1981 May; 60(5):491-8. PubMed ID: 6265138
    [No Abstract]   [Full Text] [Related]  

  • 59. Determinants of angiotensin II generation during converting enzyme inhibition.
    Juillerat L; Nussberger J; Ménard J; Mooser V; Christen Y; Waeber B; Graf P; Brunner HR
    Hypertension; 1990 Nov; 16(5):564-72. PubMed ID: 2172161
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Monitoring angiotensin-converting enzyme inhibitors].
    Bolla B; Disdier P; Roux F; Renucci JF; Vaisse B; Harle JR; Poggi L; Weiller PJ
    Presse Med; 1994 Mar; 23(10):491. PubMed ID: 8022729
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.